Sangamo Therapeutics Selects Successful Bidders Following Competitive Asset Auction

Click here to view

Additional information about the Chapter 11 reorganization and asset sales is available through Sangamo's noticing agent at https://www.veritaglobal.net/SangamoTherapeutics.

Presentation

Preclinical Development of a Novel Gene Therapy for the Treatment of Peripheral Neuropathic Pain Through Zinc Finger Repressor- Mediated Repression of the SCN9A Gene

Download PDF